NCT07161414 - A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 21, 2025

Primary Completion Date

August 27, 2026

Study Completion Date

March 28, 2028

Conditions

Advanced Solid Tumors

Interventions

DRUG

IV Rilvegostomig

Rilvegostomig administered IV.

DRUG

Recombinant Human Hyaluronidase (rHu)

rHu administered subcutaneously.

DRUG

SC Rilvegostomig

Rilvegostomig administered subcutaneously.

DRUG

SC rilvegostomig + rHu

SC rilvegostomig + rHu administered subcutaneously.